CHMP Positive Opinion for Sugemalimab in Stage III NSCLC
Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone, remarked, “We are encouraged that the EMA review for our Stage III NSCLC indication has progressed so rapidly and positively. Coming just one year after sugemalimab’s first approval in Europe for first-line metastatic squamous and non-squamous NSCLC in 2024, this marks the second positive opinion and recommendation from CHMP. If approved, sugemalimab’s role as a core immunotherapy for lung cancer will be further solidified, significantly enhancing its market presence and commercial potential. We will work closely with our partners to expedite the full commercialization of sugemalimab across European markets, making this high-quality and accessible treatment option available to more patients.”
Share:
More News
“FDA clearance of the IND for ORM-1153 is an important milestone for Orum, bringing another first-in-class DAC into the clinic and extending our approach into CD123-expressing hematologic malignancies,” said Olaf Christensen, M.D., Chief Medical Officer of Orum Therapeutics. “By combining cell-selective delivery with targeted protein degradation in a single molecule,
“We are excited to expand our clinical collaboration with Roche to evaluate a second KRAS combination with potential best-in-class MTA-cooperative PRMT5 inhibitor IDE892 for pancreatic cancer patients, where there remains a high unmet medical need. IDEAYA is advancing multiple rational combination strategies for the IDE892 program, including with MAT2A inhibitor
“These encouraging initial safety observations represent an important first step in the clinical evaluation of ZI-MA4-1 and our TCR-NK platform” said Namir Hassan, Chief Executive Officer of Zelluna. “The first patient received all three planned doses, and the independent committee’s recommendation enables us to continue recruitment at the first dose
“Receiving FTD is an important milestone for ERAS-0015 and reflects the urgent need for new therapies for patients with metastatic pancreatic cancer,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Together with the encouraging clinical activity and favorable tolerability observed to date, this FTD helps to position us